Atuveciclib (BAY-1143572)

Atuveciclib (BAY-1143572) is an inhibitor of CDK and CDK9 used in studies of Wnt Signaling and Cell Cycle Regulation. In practice, this places the compound in experiments that measure beta-catenin-dependent transcription and developmental signaling and checkpoint control, mitotic progression, and proliferation timing in cancer, cell cycle, and cell signaling models.

By inhibiting CDK and CDK9, Atuveciclib (BAY-1143572) can be used to examine beta-catenin-dependent transcription and developmental signaling and checkpoint control, mitotic progression, and proliferation timing. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CDK and CDK9
• Pathway perturbation studies connected to Wnt Signaling and Cell Cycle Regulation
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Atuveciclib (BAY-1143572) is appropriate when a defined chemical perturbant is needed to connect CDK and CDK9 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.